Apr 15 |
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
|
Apr 3 |
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
|
Apr 1 |
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
|
Mar 28 |
Can-Fite Biopharma GAAP EPS of -$0.01, revenue of $0.74M
|
Mar 28 |
Can-Fite Reports 2023 Financial Results and Clinical Update
|
Mar 11 |
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
|
Feb 28 |
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
|
Jan 30 |
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
|
Jan 29 |
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
|
Dec 20 |
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
|